Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.
Diabetes Res Clin Pract · 2021
Last updated 2026-05-28In a 16-week study of 25 obese women with PCOS, those taking 1.0 mg of semaglutide saw a reduction in tongue fat tissue (-1.94 cm) and fat proportion compared to those on a placebo (+3.12 cm and +0.04, respectively). The reductions in tongue fat were linked to decreases in body weight, BMI, and waist circumference.
AI summary of the abstract below.
| Journal | Diabetes Res Clin Pract, 2021 |
|---|---|
| Citations | 31 |
| Relative citation ratio | 2.24 |
| NIH percentile | 77 |
| Molecules | semaglutide |
| Conditions studied | Obesity, Obstructive Sleep Apnea |
Abstract
AIM: We evaluated the effect of the latest GLP-1 RA semaglutide on tongue fat storage in obese women.
DESIGN: We conducted a randomized single-blind, pilot study.
METHODS: Twenty-five obese women with polycystic ovary syndrome (PCOS) (33.7 ± 5.3 years, body mass index (BMI) 36.1 ± 3.9 kg/m2, mean ± SD) were randomized to semaglutide 1.0 mg or placebo for 16 weeks. We quantified tongue volume and its fat tissue and fat proportion by magnetic resonance imaging.
RESULTS: Tongue fat tissue and fat proportion significantly reduced after semaglutide vs placebo (-1.94 ± 5.51 vs. + 3.12 ± 4.87 cm, p = 0.022, and -0.02 ± 0.07 vs. 0.04 ± 0.06, p = 0.010, respectively). Correlation analysis revealed that these reductions were associated with those in body weight, BMI and waist circumference (p = 0.010 for all).
CONCLUSIONS: This is the first study confirming the beneficial effect of semaglutide on tongue structure in obese women with PCOS. Further studies are needed to assess the clinical importance of such findings.
Verbatim abstract via PubMed 34217774 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.